AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

INDV

841.5

-0.65%↓

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

INDV

841.5

-0.65%↓

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

INDV

841.5

-0.65%↓

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

INDV

841.5

-0.65%↓

AZN.UK

10,508

+1.12%↑

GSK

1,432

+0.99%↑

INDV

841.5

-0.65%↓

Search

Oxford Biomedica PLC

Chiusa

303.5 -0.65

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

296.5

Massimo

307

Metriche Chiave

By Trading Economics

Entrata

22M

-11M

Vendite

27M

78M

Margine di Profitto

-13.726

Dipendenti

850

EBITDA

25M

5M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+118.04% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

8M

316M

Apertura precedente

304.15

Chiusura precedente

303.5

Oxford Biomedica PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 mag 2025, 20:54 UTC

Acquisizioni, Fusioni, Takeovers

PNC to Buy Private-Equity Agent Aqueduct Capital

20 mag 2025, 20:50 UTC

Utili

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 mag 2025, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 mag 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 mag 2025, 23:39 UTC

Discorsi di Mercato

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 mag 2025, 23:08 UTC

Discorsi di Mercato

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 mag 2025, 22:45 UTC

Acquisizioni, Fusioni, Takeovers

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 mag 2025, 22:44 UTC

Notizie principali

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20 mag 2025, 22:20 UTC

Notizie principali

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 mag 2025, 22:00 UTC

Utili

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 mag 2025, 22:00 UTC

Utili

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 mag 2025, 22:00 UTC

Utili

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 mag 2025, 21:44 UTC

Utili

James Hardie Industries 4Q Adj EPS 36c >JHX

20 mag 2025, 21:44 UTC

Utili

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 mag 2025, 21:44 UTC

Utili

James Hardie Industries 4Q EPS 10c >JHX

20 mag 2025, 21:44 UTC

Utili

James Hardie Industries 4Q Sales $972M >JHX

20 mag 2025, 20:52 UTC

Notizie principali

Elon Musk to Cut Back Political Spending -- 3rd Update

20 mag 2025, 20:52 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2025, 20:52 UTC

Discorsi di Mercato

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 mag 2025, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 mag 2025, 20:28 UTC

Acquisizioni, Fusioni, Takeovers

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 mag 2025, 20:23 UTC

Acquisizioni, Fusioni, Takeovers

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 mag 2025, 20:22 UTC

Utili

XP 1Q Adj EPS BRL2.29 >XP

20 mag 2025, 20:22 UTC

Utili

XP 1Q Rev BRL4.345B >XP

20 mag 2025, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 mag 2025, 20:20 UTC

Notizie principali

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 mag 2025, 20:19 UTC

Acquisizioni, Fusioni, Takeovers

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 mag 2025, 20:11 UTC

Notizie principali

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 mag 2025, 20:09 UTC

Utili

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Confronto tra pari

Modifica del prezzo

Oxford Biomedica PLC Previsione

Obiettivo di Prezzo

By TipRanks

118.04% in crescita

Previsioni per 12 mesi

Media 649.772 GBX  118.04%

Alto 800 GBX

Basso 500 GBX

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Oxford Biomedica PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.